2 weeks Ago By ABMN Staff
Susquehanna Portfolio Strategies LLC cut its position in Neurocrine Biosciences, Inc. ( NASDAQ:NBIX – Free Report ) by 48.2% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission.
The institutional investor owned 59,455 shares of the company’s stock after selling 55,244 shares during the quarter. Susquehanna Portfolio Strategies LLC owned 0.06% of Neurocrine Biosciences worth $8,185,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors also recently made changes to their positions in NBIX. Norges Bank acquired a new position in Neurocrine Biosciences during the 4th quarter worth approximately $35,731,000. Hsbc Holdings PLC grew its holdings in Neurocrine Biosciences by 33.
3% during the 4th quarter. Hsbc Holdings PLC now owns 103,956 shares of the company’s stock worth $13,715,000 after acquiring an additional 25,975 shares during the last quarter. TD Asset Management Inc grew its holdings in Neurocrine Biosciences by 87.
1% during the 4th quarter. TD Asset Management Inc now owns 104,219 shares of the company’s stock worth $13,732,000 after acquiring an additional 48,521 shares during the last quarter. Treasurer of the State of North Carolina grew its holdings in Neurocrine Biosciences by 0.
8% during the 4th quarter. Treasurer of the State of North Carolina now owns 68,819 shares of the company’s stock worth $9,068,000 after acquiring an additional 576 shares during the last quarter. Finally, TFO Wealth Partners LLC grew its holdings in Neurocrine Biosciences by 105,900.
0% during the 4th quarter. TFO Wealth Partners LLC now owns 3,180 shares of the company’s stock worth $395,000 after acquiring an additional 3,177 shares during the last quarter. 92.
59% of the stock is currently owned by institutional investors and hedge funds. Neurocrine Biosciences Price Performance Shares of NBIX stock opened at $115.06 on Friday.
The firm has a 50-day moving average of $136.11 and a 200-day moving average of $137.61.
The company has a market cap of $11.58 billion, a P/E ratio of 31.70 and a beta of 0.
37. Neurocrine Biosciences, Inc. has a one year low of $103.
63 and a one year high of $157.98. Wall Street Analysts Forecast Growth NBIX has been the topic of a number of research reports.
JPMorgan Chase & Co. boosted their target price on shares of Neurocrine Biosciences from $173.00 to $181.
00 and gave the stock an “overweight” rating in a report on Wednesday, August 7th. Piper Sandler raised shares of Neurocrine Biosciences from a “neutral” rating to an “overweight” rating and boosted their target price for the stock from $131.00 to $159.
00 in a report on Thursday, August 29th. Morgan Stanley upped their price objective on shares of Neurocrine Biosciences from $160.00 to $170.
00 and gave the company an “overweight” rating in a research note on Friday, July 12th. BMO Capital Markets reduced their price objective on shares of Neurocrine Biosciences from $142.00 to $128.
00 and set a “market perform” rating on the stock in a research note on Thursday, August 29th. Finally, Jefferies Financial Group upped their price objective on shares of Neurocrine Biosciences from $177.00 to $189.
00 and gave the company a “buy” rating in a research note on Monday, August 19th. Five investment analysts have rated the stock with a hold rating, eighteen have issued a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat, Neurocrine Biosciences currently has an average rating of “Moderate Buy” and an average target price of $162.
20. Read Our Latest Report on NBIX Insider Activity at Neurocrine Biosciences In related news, Director William H. Rastetter sold 14,250 shares of the stock in a transaction dated Thursday, August 15th.
The shares were sold at an average price of $146.69, for a total transaction of $2,090,332.50.
Following the completion of the transaction, the director now owns 37,491 shares in the company, valued at $5,499,554.79. The transaction was disclosed in a document filed with the SEC, which is available through this link .
In related news, CFO Matt Abernethy sold 14,100 shares of the stock in a transaction dated Tuesday, August 13th. The shares were sold at an average price of $150.38, for a total transaction of $2,120,358.
00. Following the completion of the transaction, the chief financial officer now owns 31,528 shares in the company, valued at $4,741,180.64.
The transaction was disclosed in a document filed with the SEC, which is available through this link . Also, Director William H. Rastetter sold 14,250 shares of the stock in a transaction dated Thursday, August 15th.
The stock was sold at an average price of $146.69, for a total transaction of $2,090,332.50.
Following the transaction, the director now owns 37,491 shares of the company’s stock, valued at approximately $5,499,554.79. The disclosure for this sale can be found here .
Over the last 90 days, insiders sold 71,798 shares of company stock worth $10,676,096. 4.30% of the stock is owned by company insiders.
About Neurocrine Biosciences ( Free Report ) Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids. Featured Stories Want to see what other hedge funds are holding NBIX? Visit HoldingsChannel.
com to get the latest 13F filings and insider trades for Neurocrine Biosciences, Inc. ( NASDAQ:NBIX – Free Report ). Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.
com's FREE daily email newsletter ..
